Investment Thesis
Collegium Pharmaceutical demonstrates strong revenue growth (23.6% YoY) and robust free cash flow generation (29.4% margin), supported by solid balance sheet fundamentals (0.08x debt/equity). However, declining diluted EPS despite revenue expansion, weak capital returns (ROE 4.6%, ROA 0.9%), and concerning interest coverage (1.8x) signal operational challenges and potential capital inefficiency that warrant caution.
Strengths
- Strong topline growth of 23.6% YoY indicating market demand
- Excellent gross margins of 60.6% and solid operating margins of 16.0%
- Robust free cash flow generation of $56.8M (29.4% of revenue)
- Low financial leverage with 0.08x debt/equity ratio and $268.6M cash position
- Healthy liquidity ratios (current 1.71x, quick 1.62x)
Risks
- Diluted EPS declined 7.0% YoY despite 23.6% revenue growth, indicating operational or share dilution headwinds
- Dangerously low interest coverage ratio of 1.8x leaves minimal buffer for rate increases or covenant breaches
- Weak capital efficiency with ROE of 4.6% and ROA of 0.9% despite strong margins
- Large spread between operating income ($30.9M) and net income ($14.5M) suggests significant below-the-line expenses or tax burden
- Insider activity (9 Form 4 filings in 90 days) warrants monitoring for adverse signaling
Key Metrics to Watch
- EPS trajectory and earnings quality to reverse recent decline
- Interest coverage ratio trend and debt refinancing activity
- Return on equity improvement and capital allocation discipline
- Operating margin sustainability amid revenue scaling
- Free cash flow conversion rate and use of proceeds
Financial Metrics
Revenue
193.5M
Net Income
14.5M
EPS (Diluted)
$0.40
Free Cash Flow
56.8M
Total Assets
1.7B
Cash
268.6M
Profitability Ratios
Gross Margin
60.6%
Operating Margin
16.0%
Net Margin
7.5%
ROE
4.6%
ROA
0.9%
FCF Margin
29.4%
Balance Sheet & Liquidity
Current Ratio
1.71x
Quick Ratio
1.62x
Debt/Equity
0.08x
Debt/Assets
81.1%
Interest Coverage
1.78x
Long-term Debt
26.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T10:07:55.939650 |
Data as of: 2026-03-31 |
Powered by Claude AI